<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02408302</url>
  </required_header>
  <id_info>
    <org_study_id>CMC-13-0075-CTIL</org_study_id>
    <nct_id>NCT02408302</nct_id>
  </id_info>
  <brief_title>Buccal Midazolam Versus Nasal or Oral Midazolam Sedation for Minor Invasive Procedures in Children</brief_title>
  <official_title>Buccal Midazolam Versus Nasal or Oral Midazolam Sedation for Minor Invasive Procedures in Children: A Prospective Randomized Control Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Carmel Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Carmel Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Currently Midazolam sedation is the standard of care for minor invasive procedures in
      pediatric patients; its use is restricted to two routes of administration for this purpose
      oral and intranasal.

      A third route of administration (buccal) is tested and approved for seizure management. In
      the investigators' study the researchers investigate the buccal route of administration
      versus oral or intranasal administration for sedation. The investigators' hypothesis is that
      buccal route of administration is more convenient than intranasal and better absorbed than
      oral.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>April 2015</start_date>
  <completion_date type="Anticipated">March 2016</completion_date>
  <primary_completion_date type="Anticipated">February 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>time until sedation is achieved</measure>
    <time_frame>1 hour</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>duration of sedation</measure>
    <time_frame>4 hour</time_frame>
    <description>time from achieving sedation until reaching full consciousness</description>
  </primary_outcome>
  <primary_outcome>
    <measure>convenience of administration</measure>
    <time_frame>15 minutes</time_frame>
    <description>described by the parent and the physician by a numerical rating scale (NRS) questionaire</description>
  </primary_outcome>
  <primary_outcome>
    <measure>efficacy of the sedation</measure>
    <time_frame>4 hours</time_frame>
    <description>described by the parent, nurse and physician by a NRS questionaire</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Dormicum</condition>
  <condition>Conscious Sedation</condition>
  <condition>Children</condition>
  <arm_group>
    <arm_group_label>oral midazolam</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>oral midazolam 0.5-0.7 mg/kg maximum 10 mg. one dose only before the invasive procedure.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>intranasal midazolam</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>intranasal midazolam 0.3-0.5 mg/kg maximum 5 mg. one dose only before the invasive procedure</description>
  </arm_group>
  <arm_group>
    <arm_group_label>buccal midazolam</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>buccal midazolam 0.3-0.5 mg/kg maximum 5 mg. one dose only before the invasive procedure</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Midazolam</intervention_name>
    <description>comparison between 3 routes of administration of the drug Midazolam used for sedation for minor procedures in pediatric population. the routes are oral intranasal and buccal.</description>
    <arm_group_label>oral midazolam</arm_group_label>
    <arm_group_label>intranasal midazolam</arm_group_label>
    <arm_group_label>buccal midazolam</arm_group_label>
    <other_name>Dormicum</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age 5 months to 6 years.

          -  need to undergo a minimal invasive procedure that requires light sedation.

          -  ASA (American Society of Anesthesiologists) I-II

          -  parent that can read, understand and sign an informed consent form

        Exclusion Criteria:

          -  patients with life threatening conditions.

          -  patients with respiratory or cardiac chronic illnesses or ASA other than I-II.

          -  patients with traumatic injury for the nose or the oral cavity.

          -  patients that would not or cannot take the drug in the route picked in a randomized
             way.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Months</minimum_age>
    <maximum_age>6 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Muriel Konopnicki</last_name>
    <role>Principal Investigator</role>
    <affiliation>Carmal Medical Center, Haifa, Israel</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Muriel Konopnicki</last_name>
    <phone>972-4-8250240</phone>
    <email>MurielKo2@clalit.org.il</email>
  </overall_contact>
  <location>
    <facility>
      <name>Carmel Medical Center</name>
      <address>
        <city>Haifa</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Muriel Konopnicki, MD</last_name>
      <phone>972-4-8250240</phone>
      <email>MurielKo2@clalit.org.il</email>
    </contact>
    <investigator>
      <last_name>Muriel Konopnicki, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <reference>
    <citation>Krauss B, Green SM. Sedation and analgesia for procedures in children. N Engl J Med. 2000 Mar 30;342(13):938-45. Review.</citation>
    <PMID>10738053</PMID>
  </reference>
  <reference>
    <citation>Krauss B, Green SM. Procedural sedation and analgesia in children. Lancet. 2006 Mar 4;367(9512):766-80. Review.</citation>
    <PMID>16517277</PMID>
  </reference>
  <reference>
    <citation>American Academy of Pediatrics; American Academy of Pediatric Dentistry, Cot√© CJ, Wilson S; Work Group on Sedation. Guidelines for monitoring and management of pediatric patients during and after sedation for diagnostic and therapeutic procedures: an update. Pediatrics. 2006 Dec;118(6):2587-602.</citation>
    <PMID>17142550</PMID>
  </reference>
  <reference>
    <citation>Procacci P, Francini F, Zoppi M, Maresca M. Cutaneous pain threshold changes after sympathetic block in reflex dystrophies. Pain. 1975 Jun;1(2):167-75.</citation>
    <PMID>1235980</PMID>
  </reference>
  <reference>
    <citation>American Society of Anesthesiologists Task Force on Sedation and Analgesia by Non-Anesthesiologists. Practice guidelines for sedation and analgesia by non-anesthesiologists. Anesthesiology. 2002 Apr;96(4):1004-17.</citation>
    <PMID>11964611</PMID>
  </reference>
  <reference>
    <citation>Godwin SA, Caro DA, Wolf SJ, Jagoda AS, Charles R, Marett BE, Moore J; American College of Emergency Physicians. Clinical policy: procedural sedation and analgesia in the emergency department. Ann Emerg Med. 2005 Feb;45(2):177-96. Review.</citation>
    <PMID>15671976</PMID>
  </reference>
  <reference>
    <citation>Shavit I, Feraru L, Miron D, Weiser G. Midazolam for urethral catheterisation in female infants with suspected urinary tract infection: a case-control study. Emerg Med J. 2014 Apr;31(4):278-80. doi: 10.1136/emermed-2012-202088. Epub 2013 Feb 22.</citation>
    <PMID>23435653</PMID>
  </reference>
  <reference>
    <citation>McErlean M, Bartfield JM, Karunakar TA, Whitman MC, Turley DM. Midazolam syrup as a premedication to reduce the discomfort associated with pediatric intravenous catheter insertion. J Pediatr. 2003 Apr;142(4):429-30.</citation>
    <PMID>12712062</PMID>
  </reference>
  <reference>
    <citation>Lane RD, Schunk JE. Atomized intranasal midazolam use for minor procedures in the pediatric emergency department. Pediatr Emerg Care. 2008 May;24(5):300-3. doi: 10.1097/PEC.0b013e31816ecb6f.</citation>
    <PMID>18496113</PMID>
  </reference>
  <reference>
    <citation>Wiznitzer M. Buccal midazolam is effective for acute treatment of seizures. J Pediatr. 2006 Jan;148(1):143.</citation>
    <PMID>16440479</PMID>
  </reference>
  <reference>
    <citation>Wiznitzer M. Buccal midazolam for seizures. Lancet. 2005 Jul 16-22;366(9481):182-3.</citation>
    <PMID>16023491</PMID>
  </reference>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 31, 2015</study_first_submitted>
  <study_first_submitted_qc>April 2, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 3, 2015</study_first_posted>
  <last_update_submitted>April 8, 2015</last_update_submitted>
  <last_update_submitted_qc>April 8, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 9, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Carmel Medical Center</investigator_affiliation>
    <investigator_full_name>Muriel Konopnicki</investigator_full_name>
    <investigator_title>Head of Pediatric emergency room</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Midazolam</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

